• 1. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693

Introduction to 2-(p-Tolyl)spiro[3.3]heptan-2-amine (CAS No. 1487382-32-0)

2-(p-Tolyl)spiro[3.3]heptan-2-amine, with the CAS number 1487382-32-0, is a unique compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of spiro compounds, which are characterized by a central spiro atom connecting two rings. The presence of a p-tolyl group and an amine functional group imparts distinct chemical and biological properties to this molecule, making it a valuable candidate for various applications.

The structure of 2-(p-Tolyl)spiro[3.3]heptan-2-amine consists of a spiro[3.3]heptane core with a p-tolyl substituent and an amine group attached to the same carbon atom. This unique arrangement provides the compound with a combination of hydrophobic and hydrophilic properties, which can influence its solubility, stability, and biological activity. The spiro structure itself is known for its rigidity, which can enhance the compound's ability to interact with specific biological targets.

In recent years, there has been a growing interest in the development of spiro compounds for their potential therapeutic applications. 2-(p-Tolyl)spiro[3.3]heptan-2-amine has been studied for its potential as a lead compound in drug discovery due to its unique structural features and favorable physicochemical properties. Research has shown that this compound exhibits promising activity in various biological assays, including enzyme inhibition and receptor modulation.

One of the key areas of research involving 2-(p-Tolyl)spiro[3.3]heptan-2-amine is its potential as an inhibitor of specific enzymes involved in disease pathways. For example, studies have demonstrated that this compound can effectively inhibit the activity of certain kinases, which are enzymes that play crucial roles in signal transduction pathways associated with cancer and other diseases. The ability to modulate these enzymes selectively makes 2-(p-Tolyl)spiro[3.3]heptan-2-amine a promising candidate for further development as a therapeutic agent.

Beyond its enzymatic inhibition properties, 2-(p-Tolyl)spiro[3.3]heptan-2-amine has also shown potential in modulating receptor activity. Receptors are protein molecules that bind to specific ligands and trigger cellular responses. Research has indicated that this compound can interact with certain receptors, such as G protein-coupled receptors (GPCRs), which are important targets for drug development in areas such as neurology and psychiatry.

The pharmacokinetic properties of 2-(p-Tolyl)spiro[3.3]heptan-2-amine have also been investigated to assess its suitability as a drug candidate. Studies have shown that this compound exhibits favorable absorption, distribution, metabolism, excretion (ADME) properties, which are essential for ensuring that the drug reaches its intended target in the body and remains active for an appropriate duration. These properties make it an attractive candidate for further preclinical and clinical evaluation.

In addition to its potential therapeutic applications, 2-(p-Tolyl)spiro[3.3]heptan-2-amine has also been explored for its use in chemical synthesis and as a building block for more complex molecules. The unique structural features of this compound provide chemists with opportunities to design and synthesize novel derivatives with enhanced biological activities or improved pharmacological profiles.

The synthesis of 2-(p-Tolyl)spiro[3.3]heptan-2-amine involves several steps, including the formation of the spiro core and the introduction of the p-tolyl and amine groups. Various synthetic routes have been reported in the literature, each offering different advantages in terms of yield, purity, and scalability. These synthetic methods have been optimized to ensure high efficiency and reproducibility, making it feasible to produce this compound on both laboratory and industrial scales.

In conclusion, 2-(p-Tolyl)spiro[3.3]heptan-2-amine (CAS No. 1487382-32-0) is a promising compound with a unique structure that offers significant potential in medicinal chemistry and pharmaceutical research. Its ability to inhibit specific enzymes and modulate receptor activity makes it a valuable lead compound for drug discovery efforts targeting various diseases. Ongoing research continues to explore its full range of biological activities and optimize its pharmacological properties for future clinical applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)